Uveal Melanoma clinical trials
The registry lists 281 studies for Uveal Melanoma across more than 10 countries. 50 are recruiting or about to start. 234 of them are mainly about Uveal Melanoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Uveal Melanoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (22) · Institut Curie (13) · Memorial Sloan Kettering Cancer Center (11) · M.D. Anderson Cancer Center (8) · Aura Biosciences (7) · H. Lee Moffitt Cancer Center and Research Institute (7) · Vastra Gotaland Region (6) · University of Southern California (6)
What is being tested here
Drugs under test in Uveal Melanoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Tebentafusp | 5 | 1 | 9 |
| Darovasertib | 3 | 3 | 7 |
| Nivolumab | 2 | 0 | 13 |
| Melphalan | 2 | 3 | 6 |
| Lifileucel | 2 | 0 | 3 |
| Ipilimumab | 1 | 0 | 17 |
| Aflibercept | 1 | 1 | 4 |
| Roginolisib | 1 | 0 | 3 |
| Aldesleukin | 1 | 0 | 3 |
| Sturlimogene erparepvec | 1 | 1 | 2 |
Drug classes tested here Immune checkpoint inhibitors 3 open · Alkylating agents 2 open · Angiogenesis inhibitors 1 open · Tyrosine kinase inhibitors (TKIs) 1 open · HDAC inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Jan 2027IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma · Phase 3 · IDEAYA Biosciences
- Nov 2027A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma · Phase 3 · Aura Biosciences
- Dec 2026PHP and Immunotherapy in Metastasized UM · Leiden University Medical Center
- Dec 2026Resistance Exercise in Patients With Ocular Melanoma · University of Valencia
- Dec 2026Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma · University of Oxford
- Dec 2026Vorinostat in Treating Patients With Metastatic Melanoma of the Eye · National Cancer Institute (NCI)
- Jan 2027Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions · IDEAYA Biosciences
- Jan 2027Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases · Thomas Jefferson University
- Mar 2027A Prospective Natural History Study in Uveal Melanoma · Columbia University
- Mar 2027Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours · MonTa Biosciences ApS
Who these studies take
Of the 42 Uveal Melanoma studies recruiting now, 35 (83%) set no upper age limit and 4 (10%) stop at 75 or younger. 3 (7%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (2%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (7%) | 3 (7%) |
| 18 | 41 (98%) | 41 (98%) |
| 30 | 42 (100%) | 42 (100%) |
| 40 | 42 (100%) | 42 (100%) |
| 50 | 42 (100%) | 42 (100%) |
| 65 | 42 (100%) | 42 (100%) |
| 75 | 41 (98%) | 41 (98%) |
| 85 | 37 (88%) | 37 (88%) |
Across all 281 studies, recruiting or not: 5% stop at 75 or younger and <1% at 65; 10% take children; 1% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Uveal Melanoma studies take
Of 46 phase 2 interventional studies under Uveal Melanoma, half reached primary completion within 52 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 1 | 45 mo27–66 · 32 studies | — | — |
| Phase 2 | 52 mo37–84 · 46 studies | — | 55 mo37–95 · 39 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 14, 2026.
Stopped2
- Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid TumorsTerminatedNov 10, 2026NCT05075993
- Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With TebentafuspWithdrawnNov 6, 2026NCT07803562
Studies
Recruiting first, then most recently updated. Showing 50 of 281. Browse all 281 → or search them.
- Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal MelanomaRecruitingNCT07804186Phase 36 countries
- High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal Melanoma: Modern Radiation Techniques and OutcomesRecruitingNCT079134121 country
- A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid TumorsRecruitingNCT07636785Phase 1/21 country
- Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverRecruitingNCT07364474Not applicable1 country
- Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition SyndromeRecruitingNCT047924631 country
- Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on TumorsNot yet recruitingNCT07863024Phase 1/2
- A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or AngiosarcomaRecruitingNCT05607095Phase 11 country
- Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver MetastasesNot yet recruitingNCT05903937Phase 1
- Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic MelanomaNot yet recruitingNCT07183852Phase 1
- Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal MelanomaRecruitingNCT06070012Phase 21 country
- A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal MelanomaEnrolling by invitationNCT073389681 country
- Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid TumoursRecruitingNCT04855435Phase 12 countries
- Study of Neoadjuvant RBP-01 In Patients With Primary Uveal MelanomaNot yet recruitingNCT07747935Phase 1/2
- Tebentafusp-tebn With LDT in Metastatic UMRecruitingNCT06626516Phase 1/21 country
- Neoadjuvant Immunotherapy for Patients With High-risk Eye MelanomaRecruitingNCT07501117Phase 11 country
- Adjuvant Tebentafusp in High Risk Ocular MelanomaRecruitingNCT06246149Phase 39 countries
- Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaRecruitingNCT06961357Phase 1/21 country
- Adjuvant Quisinostat in High-Risk Uveal MelanomaRecruitingNCT06932757Phase 21 country
- A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive LifileucelRecruitingNCT06940739Phase 1/22 countries
- Neoadjuvant Tebentafusp for Uveal MelanomaRecruitingNCT06414590Phase 21 country
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC FusionsRecruitingNCT03947385Phase 1/23 countries
- Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced MelanomaRecruitingNCT07627698Phase 1/21 country
- ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsRecruitingNCT03686124Phase 1/22 countries
- Neoadjuvant Darovasertib in Primary Uveal MelanomaRecruitingNCT07015190Phase 321 countries
- Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisRecruitingNCT07203391Phase 11 country
- A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaRecruitingNCT06581406Phase 2/33 countries
- Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaRecruitingNCT07276386Phase 21 country
- Identification of New Candidate Genes for Hereditary Predisposition to Uveal MelanomaRecruitingNCT06550674Not applicable1 country
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsRecruitingNCT04119024Phase 11 country
- Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal MelanomaRecruitingNCT06627244Phase 21 country
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.RecruitingNCT06022029Phase 12 countries
- Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal MelanomaRecruitingNCT06121180Phase 21 country
- Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal MelanomaRecruitingNCT07136181Phase 1/21 country
- A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-KitRecruitingNCT06805825Phase 11 country
- Melphalan Chemoreduction for Ocular MelanomaEnrolling by invitationNCT05893654Phase 1/21 country
- Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)RecruitingNCT04424719Not applicable1 country
- Adding IL-2 to Tebentafusp to Eradicate Cancer ProgressionRecruitingNCT07063875Phase 1/21 country
- Resistance Exercise in Patients With Ocular MelanomaRecruitingNCT06970236Not applicable1 country
- Adjuvant Melatonin for Uveal MelanomaRecruitingNCT05502900Phase 31 country
- PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver MetastasesRecruitingNCT06519266Phase 31 country
- Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal MelanomaRecruitingNCT062800401 country
- Uveal Melanoma - Comparative StudyRecruitingNCT062845121 country
- MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck CancerRecruitingNCT04729543Phase 1/21 country
- Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method StudyNot yet recruitingNCT06073548
- Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal MelanomaRecruitingNCT058894811 country
- Retrospective Register for Uveal MelanomaRecruitingNCT057337281 country
- A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal MelanomaRecruitingNCT05077280Phase 21 country
- Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical PracticeRecruitingNCT054020591 country
- A Cohort IND Expanded Access Program for Supporting Patient Access to TebentafuspAvailableNCT04960891
- Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal MelanomaRecruitingNCT014386581 country